Forest Pharmaceuticals, Inc. (FPI) can help you see the pharmaceuticals amidst the trees. The company develops, manufactures, and distributes a variety of prescription and OTC pharmaceutical products, including both branded and generic versions. Its product line includes Aerobid (asthma), Celexa and Lexapro (depression), Cervidil (cervical ripening), Tiazac (hypertension), and Namenda (Alzheimer's disease). FPI's products are marketed to physicians, hospitals, pharmacies, and managed care organizations in the US and Puerto Rico. The company, which operates manufacturing and packaging facilities in Missouri and Ohio, is a subsidiary of Forest Laboratories.

Idera Pharmaceuticals, Inc. company was founded in 1989 and is based in Cambridge, Massachusetts. Idera Pharmaceuticals, Inc., a biotechnology company, discovers and develops DNA- and RNA-based drug candidates for the treatment of infectious diseases, autoimmune and inflammatory diseases, cancer, and asthma and allergies, and for use as vaccine adjuvants. The company designs and creates proprietary Toll-Like Receptors (TLR) to modulate immune responses, including TLR agonist, a compound that stimulates an immune response through the targeted TLR; and TLR antagonist, a compound that blocks activation of an immune response through the targeted TLR. Its drug candidates include IMO-2125, a TLR9 agonist, which is in Phase 1 clinical trial for hepatitis C virus infection; and TLR7, 8, and 9 agonists that are in research stage for viral diseases. The company also develops IMO-3100, a dual TLR7/TLR9 antagonist, which is in preclinical development stage for autoimmune and inflammatory diseases, such as lupus, rheumatoid arthritis, multiple sclerosis, psoriasis, and colitis.In addition, its drug candidates also comprise TLR7 and TLR8 agonists that are in research stage for solid tumor cancers. The company has a licensing and collaboration agreement with Merck KGaA to research, develop, and commercialize TLR9 agonists for the treatment of cancer, excluding cancer vaccines; a license and research collaboration agreement with Merck & Co., Inc. to research, develop, and commercialize therapeutic and prophylactic vaccine products containing its TLR7, 8, and 9 agonists in the fields of cancer, infectious diseases, and Alzheimer's disease; and a research collaboration and option agreement, and a license, development, and commercialization agreement with Novartis International Pharmaceutical, Ltd. to discover, develop, and commercialize TLR9 agonists for the treatment of asthma and allergies.

Pharmos Corporation was founded in 1990 and is headquartered in Iselin, New Jersey. Pharmos Corporation, a biopharmaceutical company, engages in the discovery and development of novel therapeutic drugs to treat a range of diseases of the nervous system in the United States and Israel. It focuses on the diseases of the nervous system, such as the disorders of the brain-gut axis, pain/inflammation, and autoimmune disorders. Pharmos's lead product candidate includes dextofisopam, a non-serotonergic agent, which is in Phase IIb clinical trials for the treatment of irritable bowel syndrome (IBS). Its product pipeline also includes VPI-013 that completed Phase IIa testing for the treatment of female sexual dysfunction and neuropathic pain; CB2-selective cannabinoids for the treatment of inflammatory/autoimmune diseases; and Tianeptine, which is in Phase I clinical trials for the treatment of IBS and functional dyspepsia. In addition, Pharmos Corporation's products under development comprise Cannabinor that has completed two Phase IIa proof of principle trials for treating pain; and NanoEmulsion drug delivery system, which is in Phase IIa clinical trial for the treatment of knee osteoarthritis. Pharmos's therapeutic drugs are also used to treat autoimmune disorders.

Emergent BioSolutions Inc. company was founded in 1998 and is based in Rockville, Maryland. mergent BioSolutions Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of vaccines and immune-related therapeutics in the United States, the United Kingdom, and Vietnam. The company offers BioThrax, a vaccine for preventing anthrax infection. Its advanced stage product candidates, which are in Phase II through Phase IV clinical development, include Recombinant protective antigen vaccine that comprises a purified recombinant protein with an alum adjuvant; Anthrax Immune Globulin therapeutic for the treatment of symptomatic anthrax infection; tuberculosis vaccine to prevent tuberculosis; Typhella which is a single-dose, drinkable vaccine for typhoid; Hepatitis B therapeutic vaccine for treating chronic carriers of hepatitis B infection. The company's earlier stage development product candidates comprise advanced BioThrax vaccine; Anthrax monoclonal antibody therapeutic, a human monoclonal antibody therapeutic for patients who present symptoms of anthrax disease; Recombinant botulinum vaccine to protect against illness caused by botulinum toxin; and Chlamydia vaccine for administration to adolescents to prevent disease caused by clinically relevant strains of Chlamydia trachomatis. Emergent BioSolutions Inc. has collaborations with Sanofi Pasteur and United Kingdom Health Protection Agency.

Spherotech, Inc. company was founded in 1992. pherotech is very particular about its business. Spherotech company manufactures microparticles for the drug and medical device industries. Its product offerings include ferromagnetic, fluorescent, latex, paramagnetic, and various colored microparticles. Spherotech's products are used in applications such as fluorescence and enzyme immunoassay.

Salix Pharmaceuticals, Ltd. company was founded in 1989 and is headquartered in Morrisville, North Carolina. Salix Pharmaceuticals, Ltd. is a specialty pharmaceutical company focuses on acquiring, developing and commercializing prescription drugs used in the treatment of a range of gastrointestinal diseases, which are those affecting the digestive tract. As of December 31, 2008, the Company’s products were XIFAXAN (rifaximin) Tablets 200 milligram; MOVIPREP; OSMOPREP, VISICOL Tablets, AZASAN Azathioprine Tablets, USP, 75/100 milligram; ANUSOL-HC 2.5% (Hydrocortisone Cream, USP), ANUSOL-HC 25 milligram Suppository (Hydrocortisone Acetate); PROCTOCORT Cream (Hydrocortisone Cream, USP) 1% and PROCTOCORT Suppository (Hydrocortisone Acetate Rectal Suppositories) 30 milligram; PEPCID (famotidine) for Oral Suspension; Oral Suspension DIURIL (Chlorothiazide); APRISO (mesalamine) extended-release capsules 0.375 grams, and COLAZAL (balsalazide disodium) Capsules 750 milligram.

Promega helps researchers plumb the depths of the life sciences. The company sells more than 2,000 products that allow scientists to conduct various experiments in gene, protein, and cellular research. Its reagents and other goods fall into more than two dozen categories, including DNA and RNA purification, genotype analysis, protein expression and analysis, and DNA sequencing. Promega has branches in about a dozen countries around the world. The firm sells its products directly and through more than 50 distributors. Customers include academic, pharmaceutical, and clinical labs, as well as government agencies and energy and chemical companies.

Valeant Pharmaceuticals was founded in 1960 and is headquartered in Aliso Viejo, California. Valeant Pharmaceuticals International is a multi-national specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products. The Company focuses on the therapeutic areas of dermatology and neurology. Its products are sold through three segments: Specialty Pharmaceuticals, Branded Generics (Europe) and Branded Generics (Latin America). In January 2008, the Company sold its product rights to Three Rivers Pharmaceuticals, LLC. In June 2008, the Company sold its subsidiaries in Argentina and Uruguay. In September 2008, the Company sold its business operations located in Western and Eastern Europe, Middle East and Africa (the WEEMEA business) to Meda AB of Sweden. In October 2008, the Company completed a worldwide License and Collaboration Agreement with Glaxo Group Limited, a wholly owned subsidiary of GlaxoSmithKline plc. In May 2009, the Company acquired EMO-FARM Ltd., a privately held company located in Poland.

Medivation, Inc. was founded in 2003 and is based in San Francisco, California. Medivation, Inc., a biopharmaceutical company, focuses on the development of small molecule drugs for the treatment of Alzheimer's disease, Huntington's disease, and castration-resistant prostate cancer. Its product pipeline includes Dimebon, which is in pivotal Phase 3 trial in patients with mild-to-moderate Alzheimer's disease, and is in Phase 2 clinical trial in patients with mild-to-moderate Huntington's disease; and MDV3100, a Phase 1-2 clinical trial product in patients with castration-resistant prostate cancer. The company has a collaboration agreement with Pfizer Inc to develop and commercialize Dimebon for the treatment of Alzheimer's and Huntington's diseases, as well as an agreement to develop and commercialize MDV3100, an investigational drug for the treatment of prostate cancer.

Noven Pharmaceuticals, Inc. company develops drugs using its transdermal drug delivery system, which administers medication through a patch attached to the skin. Noven's patches include such female hormone replacement therapy products as Vivelle-Dot and CombiPatch, ADHD drug Daytrana (marketed by Shire), and a transmucosal lidocaine patch used for dental procedures. The company also produces and markets three psychiatric drugs. In 2009 Noven was acquired by Japanese drug-maker Hisamitsu Pharmaceutical for some $430 million.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.